Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration

Retina

Volumn 27, Issue 4, 2007, Pages 445-450

  Chen, Eric ^a   Kaiser, Richard S ^a   Vander, James F ^a  

^a WILLS EYE HOSPITAL   (United States)

Author keywords

Age related macular degeneration; Bevacizumab; Choroidal neovascularization; Intravitreal; Pigment epithelial detachment; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; TRIAMCINOLONE ACETONIDE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; FEMALE; HUMAN; LASER THERMOTHERAPY; MALE; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; RETINA ANGIOGRAPHY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; PIGMENT EPITHELIUM OF EYE; RETINAL DETACHMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 34247238315     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iae.0000249574.89437.40     Document Type: Article

References (12)

1. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572.
2. Poliner LS, Olk RJ, Burgess D, et al. Natural history of retinal pigment epithelial detachments in age-related macular degeneration. Ophthalmology 1986;93:543-551.
3. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
4. Axer-Siegel R, Ehrlich R, Rosenblatt I, et al. Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol 2004;122:453-459.
5. Nicolo M, Ghiglione D, Lai S, et al. Intravitreal triamcinolone in the treatment of serous pigment epithelial detachment and occult choroidal neovascularization secondary to agerelated macular degeneration. Eur J Ophthalmol 2005;15:415-419.
6. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-118.
7. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
8. Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113:632.
9. Heier JS, Shapiro H, Singh AA Sr, et al. Randomized, controlled phase III study of ranibizumab (Lucentis) for minimally classic or occult neovascular age-related macular degeneration: two-year efficacy results of the MARINA study. Invest Ophthalmol Vis Sci 2006;47:E-abstract 2959.
10. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331.
11. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
12. Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30:287-290.